Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zenith

Executive Summary

Generic manufacturer indicates in a Feb. 9 release that it is making progress in bringing back products recalled under a June 1986 agreement between the company and FDA. Zenith said that at present products for which supplements have not yet been approved "accounted for approximately 9% of company sales" during the first half of 1986. "The comparable figure at the time the company's quarterly report was filed in mid-November was 21% [of first half sales]," Zenith said.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS011487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel